United States: CMS's Mandatory Radiation Oncology Payment Model: Negative Reactions In The Radiation Oncology Treatment Community

On July 10 2019, the Centers for Medicare & Medicaid Services ("CMS") issued a Notice of Proposed Rulemaking ("NPR") entitled, "Medicare Program; Specialty Care Models to Improve Quality of Care and Reduce Expenditures." In the NPR, CMS proposes to implement two new mandatory specialty care payment models – one of which, the Radiation Oncology Model ("RO Model"), applies to selected radiation therapy ("RT") services1 as provided by physician group practices, hospital outpatient departments, and freestanding radiation therapy centers, all located within randomly selected geographic areas throughout the country.

Although the proposed RO Model is consistent with broader trends in the healthcare industry to cut healthcare costs and increase quality through the use of bundled and other alternative (i.e., not fee-for-service) payment methodologies, the RO Model has garnered its fair share of detractors within the RT community.

In this article, we will focus on the concerns of such detractors, including those voiced by proton therapy providers who consider the RO Model's payment reductions – which apply to all RT providers regardless of the treatment modality at issue – as a CMS-intended financial hit against proton beam therapy. Proton beam therapy is a form of radiation treatment that the Medicare Payment Advisory Commission ("MedPAC"), in its "June 2018 Report to the Congress: Medicare and the Health Care Delivery System," (the "MedPac Report") once referred to as a "potentially low value" treatment modality and an example of why CMS should consider the development and implementation of new RT payment models to create, "incentives for organizations to reduce low-value services."

The RO Model: A Summary

As proposed, the RO Model is a prospective payment system that reimburses RT providers for RT treatment planning, technical preparation and special services, RT delivery, and RT management on a bundled basis (including both the technical and professional components of the RT services) for a 90-day episode of care. As described in the NPR, the RO Model creates a quality-based payment system that is intended to, "reduce Medicare, Medicaid, and Children's Health Insurance Program (CHIP) expenditures while preserving or enhancing the quality of [radiation therapy services] to the beneficiaries of such programs." The RO Model links RT payments to quality through the assessment of RT provider-reported quality data against traditional quality metrics including patient satisfaction thresholds. Finally, RO Model payments do not differentiate between the type of RT provider, the RT modality, or the RT modality's cost.

According to the NPR, the RO Model is currently set to take effect on January 1, 2020 and will last for five (5) years.


Section 3(b) of the Patient Access and Medicare Protection Act ("PAMPA") (P.L. 114-115) requires the Secretary of Health and Human Services to submit a report to Congress on the development of an episodic alternative payment model for the provision of radiation therapy services furnished in non-facility settings. In short, episodic alternative payment models (also called "bundled payment models") are alternative payment methods in which the payer sets a single spending target for all applicable health care services furnished during a clinical episode of care over a specified period. The RO Model is one such alternative payment model.

On November 3, 2017, the Center for Medicare and Medicaid Innovation ("CMS Innovation Center"), a component within the Center for Medicare and Medicaid Services ("CMS"), complied with PAMPA and released Report to Congress: Episodic Alternative Payment Model for Radiation Therapy Services (the "Report"). As summarized by CMS, the Report identified three reasons why, "radiation therapy is ready for payment and service delivery reform: the lack of site neutrality for payments; incentives that encourage volume of services over the value of services; and coding and payment challenges."

As one example of how these "three reasons" are reflected in the RO Model, the Report and in the NPR, the RO Model's episodic payments are calculated based upon CMS-proposed national base rates, trend factors, and adjustment factors applied to each participating RT provider. Such adjustment factors include each RT provider's case-mix, historical experience, and geographic location. As for those adjustment factors that are not included in the RO Model payment calculation, the adjustment factors do not include adjustments based upon the type of RT provider (the site-neutrality component) or the type of RT modality at issue. The absence of such adjustment factors are important in that they explain, in some part, the concerns of those in the RT provider community who take issue with the RO Model.

The RO Model: The Word from the Front

In addition, industry associations like the American Hospital Association ("AHA") and the Community Oncology Alliance ("COA"), have been critical of various aspects of the RO Model payment methodology. As described below, some of the fears expressed by AHA, COA and their constituents relate to the payment adjustment factors that are not included in the RO Model payment calculation methodology.

For example, in its September 16, 2019 comment letter to the NPR, COA writes that although it appreciates the benefits of value-based reimbursement structures, it has significant concerns regarding some of the RO Model parameters. Specifically:

  1. The COA objects to the RO Model as a mandatory demonstration project that, "fundamentally and effectively [changes] Medicare reimbursement policies" for those RT providers located in the CMS-selected geographies where the RO Model is to be tested. The COA maintains that the RO Model should be voluntary because, "not all RT providers have the infrastructure, commitment, and organizational buy-in to succeed in new payment arrangements." Moreover, the COA notes that if RT providers are required to participate, they may not have adequate support to achieve the RO Model's goals – the provision of high quality RT services at lower rates – while ensuring that they continue to meet the needs of their patients; and
  2. Because the RO Model is designed to reimburse more expensive RT treatments at the same rate as lower cost treatments, the COA is concerned that the RO Model will have a disproportionately negative financial impact on those RT providers who treat high acuity and high cost patient populations as compared to those RT providers who treat comparatively lower acuity and lower cost patient populations. In order to accommodate the treatment of patient populations with varying acuity levels with a variety of RT modalities, the COA recommends that the national base amount calculation be adjusted to reflect the costs of treating both higher and lower acuity oncology patients with a variety of RT modalities. In doing so, the COA argues that the RO Model payments, even before the adjustment factors are applied, will be more sensitive to the diversity of RT providers and patients who are going to be impacted by the RO Model.

As noted by the AHA in its September 16, 2019 comment letter, although the AHA and its member organizations share a mutual desire with CMS to move towards a more accountable and streamlined system of care, the AHA's RO Model concerns arise from a difference of opinion regarding how to best pursue this shared goal. The AHA believes that the RO Model as described in the NPR would place too much risk and burden on providers with little opportunity for shared savings as a reward. In order to address these concerns the AHA Letter calls for the following revisions to RO Model:

  1. Make the model retrospective rather than prospective, to allow CMS to reconcile providers' historical and actual case mix and avoid under or over payments;
  2. Replace the RO Model's historical experience and efficiency adjustments with an adjustment that blends participants' historical performance and national and regional average performance, as has been done in other models;
  3. Lower the discount amount, especially for the technical component (TC) payment, to 2.5% – 2.75%;
  4. Incorporate a stop-loss provision into the RO Model;
  5. Develop approaches to ensure that appropriate payments are made when providers introduce new service lines or technologies that were not included in their historical data; and
  6. Ensure that appropriate payments are made for patients treated with multiple RT modalities or with multiple cancer types.

In addition to the foregoing, the AHA, like the COA, is concerned that by making the RT Model mandatory for those RT providers located in the selected geographic area creates an unfair and unnecessary burden on the providers who have no choice but to participate in the RT Model program. As noted by the AHA, "the hospitals and health systems that would be required to participate in [the RO Model] are of many different sizes and types and are at different points in the process of transitioning to value-based care. They should not be required to participate in such a complicated program, which includes 17 different types of cancer, if they do not believe it will benefit the patients they serve." This concern about the mandatory nature of the RO Model is a common one that is shared by many providers and provider organizations.

The RO Model and its Potential Impact on Innovation and New Technology: The Case for Proton Beam Therapy

New Technology and RT Therapy. In addition to the above concerns, some stakeholders have objected to the reimbursement reductions that are part and parcel to the RO Model as creating a possible chilling effect on RT-related innovation and the development and use of new RT technology.

If the reimbursement reductions make innovation and certain types of cutting edge RT therapies economically unfeasible, RT providers who are innovating through the use of new (and often more expensive) technology to create more RT treatment alternatives that may be more specific and efficacious in the treatment of certain types of cancer and/or cancer more broadly as it may appear in rare cases may be forced to shift away from – or abandon altogether – the development and use of such new technology and new therapies. As a result, oncologists and their patients may soon find themselves with fewer (and possibly less effective) RT alternatives to choose from.

Proton Beam Therapy. A prime example of the potential negative impact that the RO Model may have on the proliferation of innovation in the RT arena can be best understood through the reaction of proton beam therapy providers and professional associations to the RO Model.

In the NPR, CMS calls out proton beam therapy as an expensive RT treatment modality that may be adversely and significantly impacted by the RO Model. For example, in the NPR, CMS notes that The Institute for Clinical and Economic Review ("ICER"), after evaluating the evidence of the overall net health benefit (which takes into account clinical effectiveness and potential harms) of proton beam therapy in comparison with other RT treatment alternatives, concluded that, "[proton beam therapy] has superior net health benefit for ocular tumors and incremental net health benefit for adult brain and spinal tumors and pediatric cancers." In addition, CMS notes that, "ICER judged that proton beam therapy is comparable with alternative treatments for prostate, lung, and liver cancer, although the strength of evidence was low for these conditions."

In response to the ICER conclusions, as well as the MediPac Report conclusions referenced above, CMS wrote in the NPR that, "[g]iven the continued debate around the benefits of [proton beam therapy], and understanding that [proton beam therapy] is more costly, we believe that it would be appropriate to include [proton beam therapy] in the RO Model's test, which is designed to evaluate, in part, site neutral payments for RT services." Notwithstanding the foregoing, CMS noted in the NPR that proton beam therapy, if provided to patients who are enrolled in federally-funded, multi-organizational, randomized control clinical trials, may be excluded from the RO Model's reach. Finally, the NPR includes CMS's request for public comment regarding the inclusion of proton beam therapy in the RO Model.

On September 16, 2019, the Alliance for Proton Therapy Access (the "APTA") submitted to CMS its comment letter to the NPR and CMS's inclusion of proton beam therapy in the five-year RO Model implementation plan. In its comment letter, APTA writes that if the RO Model will not exclude proton beam therapy completely, CMS should minimize the negative impact that the RO Model would have on cancer patients who benefit from proton therapy. APTA suggests three changes in its comment letter that would minimize the negative impact: (i) make the RO Model voluntary; (ii) encourage more evidence-gathering on proton therapy by expanding the exclusion parameters to include proton patients enrolled in all clinical trials and data registries; and (iii) create a more appropriate base rate for reimbursement that won't disincentivize providers from recommending proton therapy when it's the best treatment option.

The APTA's comment letter sums up many of the RO Model concerns that seem to be commonly accepted within the proton beam therapy provider and trade association communities. According to the APTA,

Overall, the Alliance is concerned that CMS's large cost-saving goal and scope of this RO Model puts patients at risk. We fear this aggressive approach will be disruptive to providers who are likely to no longer offer these life-saving services because the reimbursement rates you are proposing will not come close to covering the cost of PBT, thereby preventing Medicare beneficiaries from accessing this medically proven method of treating certain types of cancer. We believe that Medicare patients should be able to receive the best treatment that is recommended by their oncologists, and this rule may prevent thousands of Medicare beneficiaries from doing so. Cancer patients deserve the right to work directly with their doctors to make the best choices about their treatment options – choices that improve their chances of survival and preserve their quality of life. In our opinion, the proposed rule will take away those choices from far too many patients, leading to potentially devastating consequences including unnecessary suffering and, in some cases, death.

The Final Rule is anticipated to be published mid to late November. The RT community will be watching and so will we.


1 The selected RT services are EBRT (External Beam Radiation Therapy), IMRT (Intensity-Modulated Radiation Therapy), SRS (Stereotactic Radiosurgery), SBRT (Stereotactic Body Radiation Therapy), Proton Beam Therapy, IORT (Intraoperative Radiation Therapy), IGRT (Image-Guided Radiation Therapy), and Brachytherapy

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
19 Nov 2019, Panel, New York, United States

We have assembled a panel of experts and prepared a simulation of a series of common crises facing retail and fashion companies today, including cybersecurity and privacy issues and retail advertising and marketing issues.

19 Nov 2019, Webinar, Los Angeles, United States

Advertising has changed a great deal in recent years, and brands are facing mounting pressure to look for creative and innovative ways to resonate with their consumers.

20 Nov 2019, Webinar, Los Angeles, United States

This activity has been approved for Minimum 1 Continuing Legal Education credit by the State Bar of California.

Similar Articles
Relevancy Powered by MondaqAI
Akin Gump Strauss Hauer & Feld LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Akin Gump Strauss Hauer & Feld LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions